Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1886036 | 0.91 | HDAC1 (0.84) | HDAC1SMN1; SMN2LMNANLRP3MAPT | |
| SCHEMBL1893628 | 0.88 | HDAC1 (0.79) | HDAC1LMNAMAPTALDH1A1RAB9A | |
| SCHEMBL1884367 | 0.87 | HDAC1 (0.77) | HDAC1SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL3577206 | 0.85 | HDAC1 (0.74) | HDAC1SMN1; SMN2NLRP3MAPTALDH1A1 | |
| SCHEMBL1888025 | 0.85 | HDAC1 (0.74) | HDAC1LMNAMEN1KMT2ACSNK1D | |
| SCHEMBL1889591 | 0.85 | HDAC1 (0.79) | HDAC1SMN1; SMN2LMNANLRP3MAPT | |
| SCHEMBL1891506 | 0.85 | HDAC1 (1.00) | HDAC1SMN1; SMN2 | |
| SCHEMBL1884503 | 0.85 | HDAC1 (1.00) | HDAC1 | |
| SCHEMBL4090044 | 0.81 | HDAC1 (0.68) | HDAC1SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL12663159 | 0.81 | HDAC1 (0.67) | HDAC1SMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | claimed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | claimed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1677731-A4 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| EP-1677731-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | Aton Pharma, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005034880-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005034880-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | BRDT, TXN, TXNRD2 | HDAC1 9/4885SMN1; SMN2 1394/4885LMNA 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.